Gastric Cancer Foundation Founder, Joseph Peter Gallagher, Loses Battle With Stomach Cancer
April 03, 2013 11:33 ET
|
Gastric Cancer Foundation
SAN CARLOS, CA--(Marketwired - Apr 3, 2013) - Joseph Peter (J.P.) Gallagher, passionate advocate of finding a cure for stomach cancer, passed away on February 26 after surviving stomach cancer for...
Sir Ken Robinson to Provide Keynote Address for Parents Education Network Education Revolution 2013 Event at AT&T Park
March 26, 2013 08:00 ET
|
Parents Education Network
SAN FRANCISCO, CA--(Marketwire - Mar 26, 2013) - Parents Education Network (PEN) today announced that Sir Ken Robinson, TED speaker, celebrated author and internationally recognized leader in the...
Virus Engineered to Express Melanin Offers New Possibilities to Diagnose and Treat Solid Tumor Cancers
February 11, 2013 15:00 ET
|
Genelux
SAN DIEGO, CA--(Marketwire - Feb 11, 2013) - In a study released today in Proceedings of the National Academy of Sciences (PNAS), entitled "Vaccinia virus mediated melanin production allows MR and...
First Patient Treated in Genelux Phase I Trial With GL-ONC1 at Memorial Sloan Kettering Cancer Center
February 06, 2013 08:34 ET
|
Genelux
SAN DIEGO, CA--(Marketwire - Feb 6, 2013) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based cancer therapies and companion diagnostics, today...
Genelux Corporation Announces Early Results of a Phase I/II Clinical Trial of Virotherapeutic GL-ONC1 in Advanced Peritoneal Cavity Cancers
November 01, 2012 08:00 ET
|
Genelux Corporation
SAN DIEGO, CA--(Marketwire - Nov 1, 2012) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus based oncolytic cancer therapies and companion diagnostics,...
Genelux Corporation Announces Ground-Breaking Clinical Study Evaluating Oncolytic Vaccinia Virus in Canine Cancer Patients
June 28, 2012 11:00 ET
|
Genelux Corporation
SAN DIEGO, CA--(Marketwire - Jun 28, 2012) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based oncolytic (cancer-killing) therapies and companion...
Genelux Corporation Announces First Patient Dosed in Phase I Combination Clinical Trial of GL-ONC1
June 14, 2012 08:00 ET
|
Genelux
SAN DIEGO, CA--(Marketwire - Jun 14, 2012) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based oncolytic (cancer-killing) therapies and companion...
Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers
May 31, 2012 09:15 ET
|
Genelux
SAN DIEGO, CA--(Marketwire - May 31, 2012) - Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class,...
Genelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, Its Oncolytic Virus Lead Product Candidate
May 30, 2012 13:17 ET
|
Genelux
SAN DIEGO, CA--(Marketwire - May 30, 2012) - Genelux Corporation, a privately held, clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class,...